New Board Appointments May 2024

Orion Collaboration Announcement

Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target

Evariste joins NVIDIA Inception

Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.

AACR Annual Meeting 2024

Evariste will be attending and presenting two posters at the AACR Annual Meeting 2024

Evariste Synthetic Accessibility Scoring

ESA Scoring allows dynamic assessment of compound accessibility, enabling rapid decision-making for medicinal chemistry efforts

Sources of Uncertainty

Modeling of uncertainty is a useful process in drug discovery, with a Bayesian model significantly outperforming a naive approach.

DDR Inhibitors Summit 2024

Evariste is attending the 7th DDR Inhibitors Summit, held in Boston, MA from January 30th-Feburary 1st.

Development of a Covid antiviral

Our efforts to contribute to the Covid Moonshot project, which is focused on identifying a drug targeting the SARS-CoV-2 main protease.

Frobenius 2.0: Optimising towards potent, soluble antimalarials

Discover Frobenius 2.0, a tool for optimising the development of effective and soluble antimalarial drugs.

Automated design of potent antimalarials

The OpenSource Malaria project team used a tool called Frobenius to design and synthesize novel anti-malarial compounds.

Enhancing Frobenius Discovery with Physics-Based Simulations

Explore how NES and PoseDB improve binding energy predictions and ML accuracy in drug discovery

Orion Collaboration Announcement

Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target

Evariste joins NVIDIA Inception

Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.

AACR Annual Meeting 2024

Evariste will be attending and presenting two posters at the AACR Annual Meeting 2024

Evariste Synthetic Accessibility Scoring

ESA Scoring allows dynamic assessment of compound accessibility, enabling rapid decision-making for medicinal chemistry efforts

Sources of Uncertainty

Modeling of uncertainty is a useful process in drug discovery, with a Bayesian model significantly outperforming a naive approach.

DDR Inhibitors Summit 2024

Evariste is attending the 7th DDR Inhibitors Summit, held in Boston, MA from January 30th-Feburary 1st.

Development of a Covid antiviral

Our efforts to contribute to the Covid Moonshot project, which is focused on identifying a drug targeting the SARS-CoV-2 main protease.

Frobenius 2.0: Optimising towards potent, soluble antimalarials

Discover Frobenius 2.0, a tool for optimising the development of effective and soluble antimalarial drugs.

Automated design of potent antimalarials

The OpenSource Malaria project team used a tool called Frobenius to design and synthesize novel anti-malarial compounds.

Enhancing Frobenius Discovery with Physics-Based Simulations

Explore how NES and PoseDB improve binding energy predictions and ML accuracy in drug discovery

Orion Collaboration Announcement

Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target

Evariste joins NVIDIA Inception

Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.

AACR Annual Meeting 2024

Evariste will be attending and presenting two posters at the AACR Annual Meeting 2024

Evariste Synthetic Accessibility Scoring

ESA Scoring allows dynamic assessment of compound accessibility, enabling rapid decision-making for medicinal chemistry efforts

Sources of Uncertainty

Modeling of uncertainty is a useful process in drug discovery, with a Bayesian model significantly outperforming a naive approach.

DDR Inhibitors Summit 2024

Evariste is attending the 7th DDR Inhibitors Summit, held in Boston, MA from January 30th-Feburary 1st.

Development of a Covid antiviral

Our efforts to contribute to the Covid Moonshot project, which is focused on identifying a drug targeting the SARS-CoV-2 main protease.

Frobenius 2.0: Optimising towards potent, soluble antimalarials

Discover Frobenius 2.0, a tool for optimising the development of effective and soluble antimalarial drugs.

Automated design of potent antimalarials

The OpenSource Malaria project team used a tool called Frobenius to design and synthesize novel anti-malarial compounds.

Enhancing Frobenius Discovery with Physics-Based Simulations

Explore how NES and PoseDB improve binding energy predictions and ML accuracy in drug discovery

Orion Collaboration Announcement

Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target

Evariste joins NVIDIA Inception

Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.

AACR Annual Meeting 2024

Evariste will be attending and presenting two posters at the AACR Annual Meeting 2024

Evariste Synthetic Accessibility Scoring

ESA Scoring allows dynamic assessment of compound accessibility, enabling rapid decision-making for medicinal chemistry efforts

Sources of Uncertainty

Modeling of uncertainty is a useful process in drug discovery, with a Bayesian model significantly outperforming a naive approach.

DDR Inhibitors Summit 2024

Evariste is attending the 7th DDR Inhibitors Summit, held in Boston, MA from January 30th-Feburary 1st.

Development of a Covid antiviral

Our efforts to contribute to the Covid Moonshot project, which is focused on identifying a drug targeting the SARS-CoV-2 main protease.

Frobenius 2.0: Optimising towards potent, soluble antimalarials

Discover Frobenius 2.0, a tool for optimising the development of effective and soluble antimalarial drugs.

Automated design of potent antimalarials

The OpenSource Malaria project team used a tool called Frobenius to design and synthesize novel anti-malarial compounds.

Enhancing Frobenius Discovery with Physics-Based Simulations

Explore how NES and PoseDB improve binding energy predictions and ML accuracy in drug discovery

Orion Collaboration Announcement

Orion Corporation Enters Collaboration With Evariste to Design Inhibitors of an Undisclosed Target

Evariste joins NVIDIA Inception

Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.

AACR Annual Meeting 2024

Evariste will be attending and presenting two posters at the AACR Annual Meeting 2024

Evariste Synthetic Accessibility Scoring

ESA Scoring allows dynamic assessment of compound accessibility, enabling rapid decision-making for medicinal chemistry efforts

Sources of Uncertainty

Modeling of uncertainty is a useful process in drug discovery, with a Bayesian model significantly outperforming a naive approach.

DDR Inhibitors Summit 2024

Evariste is attending the 7th DDR Inhibitors Summit, held in Boston, MA from January 30th-Feburary 1st.

Development of a Covid antiviral

Our efforts to contribute to the Covid Moonshot project, which is focused on identifying a drug targeting the SARS-CoV-2 main protease.

Frobenius 2.0: Optimising towards potent, soluble antimalarials

Discover Frobenius 2.0, a tool for optimising the development of effective and soluble antimalarial drugs.

Automated design of potent antimalarials

The OpenSource Malaria project team used a tool called Frobenius to design and synthesize novel anti-malarial compounds.

Enhancing Frobenius Discovery with Physics-Based Simulations

Explore how NES and PoseDB improve binding energy predictions and ML accuracy in drug discovery